- Open Access
Biventricular adaptation to volume overload in mice with aortic regurgitation
© Berry et al; licensee BioMed Central Ltd. 2009
Received: 06 June 2009
Accepted: 11 August 2009
Published: 11 August 2009
Aortic valve regurgitation is usually caused by impaired coaptation of the aortic valve cusps during diastole. Hypercholesterolemia produces aortic valve lipid deposition, fibrosis, and calcification in both mice and humans, which could impair coaptation of cusps. However, a link between hypercholesterolemia and aortic regurgitation has not been established in either species. The purpose of this study was to ascertain the prevalence of aortic regurgitation in hypercholesterolemic mice and to determine its impact on the left and right ventricles.
Methods and Results
Eighty Ldlr-/-/Apob100/100/Mttpfl/fl/Mx1Cre+/+ ("Reversa") hypercholesterolemic mice and 40 control mice were screened for aortic regurgitation (AR) with magnetic resonance imaging at age 7.5 months. The prevalence of AR was 40% in Reversa mice, with moderate or severe regurgitation (AR+) in 19% of mice. In control mice, AR prevalence was 13% (p = 0.004 vs. Reversa), and was invariably trace or mild in severity. In-depth evaluation of cardiac response to volume overload was performed in 12 AR-positive and 12 AR-negative Reversa mice. Regurgitant fraction was 0.34 ± 0.04 in AR-positive vs. 0.02 ± 0.01 in AR-negative (mean ± SE; p < 0.001). AR-positive mice had significantly increased left ventricular end-diastolic volume and mass and reduced ejection fraction in both ventricles. When left ventricular ejection fraction fell below 0.60 in AR-positive (n = 7) mice, remodeling occurred and right ventricular systolic function progressively worsened.
Hypercholesterolemia causes aortic valve regurgitation with moderate prevalence in mice. When present, aortic valve regurgitation causes volume overload and pathological remodeling of both ventricles.
Mild chronic aortic regurgitation occurs with a prevalence of about 9% in women and 13% in men. Moderate or severe aortic regurgitation is less common, but the prevalence doubles with each decade of advancing age. The clinical course of patients with aortic regurgitation is determined by the severity of valve regurgitation as well as the extent to which ventricular remodeling compensates for volume overload[2, 3].
Aortic regurgitation is usually caused by defective coaptation of valve cusps during diastole, which can arise from a variety of diseases of the valve itself or the aortic root. In humans, hypercholesterolemia is a risk factor for aortic stenosis and aortic sclerosis, but a causal link with aortic regurgitation has not been established. Hypercholesterolemic Reversa mice (Ldlr-/-/Apob100/100/Mttpfl/fl/Mx1Cre+/+)  develop oxidant stress in the aortic valve  and a programmed injury response leading to valve calcification[7, 8].
In the current study, we tested the hypotheses that hypercholesterolemia causes aortic valve regurgitation in mice, and that ensuing volume overload leads to pathological remodeling of both ventricles.
Reversa mice (Ldlr-/-/Apob100/100/Mttpfl/fl/Mx1Cre+/+) have been described previously. In brief, these are severely hypercholesterolemic mice in which the hypercholesterolemia can be "switched off" by Cre-mediated inactivation of the gene for microsomal triglyceride transfer protein. Beginning 1.5 months of age, Reversa mice received a Western diet (#7088137, Harlan-Tiklad, 42% of calories from fat, 0.25% cholesterol), leading to average total cholesterol ~900 mg/dl. At age 7.5 months, 80 Reversa mice (45 males and 35 females) and 40 normocholesterolemic control mice were screened by cardiovascular magnetic resonance (CMR) for aortic regurgitation. The control group included C57BL/6 mice (n = 19); superoxide dismutase knockout mice (n = 10); interleukin-10 knockout mice (n = 7), and Reversa mice in which the hypercholesterolemia had been eliminated by inducing the Cre transgene with an injection of polyinosinic-polycytidylic ribonucleic acid (pIpC) at age 1 month (n = 4). Control mice were fed normal chow throughout the study period. We studied a genetically diverse group of control mice to exclude the possibility that findings in Reversa mice were due to a "passenger gene" rather than the hypercholesterolemia per se. All experimental procedures were approved by the Office of Animal Resources at the University of Iowa.
After CMR screening, 12 Reversa mice (7 male, 5 female) with moderate or severe aortic regurgitation (AR+), and an additional 12 Reversa mice without aortic regurgitation (AR-) underwent comprehensive CMR evaluation of right and left ventricular size and systolic function. Twelve of these mice subsequently entered a study examining cellular and molecular responses to cholesterol-lowering at a later age, which is reported elsewhere. Aortic regurgitation and ventricular function were not examined in that study.
Screening for aortic regurgitation
The presence and severity of aortic regurgitation were determined by adaptation and modification of a convention introduced by Higgins et al. Aortic regurgitation causes dephasing of "white blood" in the left ventricular outflow tract during early diastole (before mitral valve opening). Severity was estimated by the length of the dephasing jet in relation to the valve-apex distance in the long-axis (mild, < 25% of valve-apex distance; moderate, 25–50%; severe: > 50%). Where image quality was sufficient (n = 71 Reversa mice and 32 control mice, respectively), aortic root diameter was measured at the sinotubular junction using electronic calipers.
Assessment of ventricular structure and function
Hypercholesterolemic Reversa mice with moderate or severe aortic regurgitation (n = 12) and an equal number of hypercholesterolic AR- Reversa mice underwent a more thorough evaluation of ventricular size and function. Using the same imaging pulse sequence, images were acquired in 1-mm contiguous planes aligned with the left ventricular short axis. The entire left and right ventricles were imaged in 8–12 slices in 15–20 phases spanning the cardiac cycle.
Left ventricular (LV) and right ventricular (RV) end-diastolic and end-systolic borders were visually identified and electronically planimetered in each slice. End-diastolic and end-systolic volumes, stroke volumes (SV), and left ventricular mass were calculated with software designed for this purpose (MedisR, Rotterdam, Netherlands) using Simpson's Rule. Regurgitant fraction (RgF) was calculated using the standard convention: RgF = (LVSV - RVSV)/LVSV
Absence of hemodynamically important aortic valve stenosis was confirmed by visual inspection of aortic valve cusp excursion in the CMR images, and in each case was confirmed by echocardiography. Significant tricuspid and mitral valve regurgitation were excluded by the absence of systolic atrial blood dephasing; pulmonic valve regurgitation was excluded by an absence of retrograde diastolic dephasing arising from the valve region.
Group data are reported as mean ± SE. Analysis of variance was used to compare continuous variables between groups. The proportion of hypercholesterolemic mice with aortic regurgitation was compared to the proportion of normocholesterolemic mice with aortic regurgitation with the Comparison of Two Proportions test.
The authors had full access to the data and take responsibility for its integrity. All authors have read and agree to the manuscript.
Effects of aortic regurgitation on ventricular anatomy and function.
452 ± 26
445 ± 39
31.3 ± 1.6
58.4 ± 8.8
6.9 ± 1.5
27.4 ± 7.6
24.4 ± 1.7
31.7 ± 2.9
0.79 ± 0.04
0.60 ± 0.05
48.6 ± 3.3
74.6 ± 7.8
0.68 ± 0.05
0.77 ± 0.05
0.02 ± 0.01
0.34 ± 0.04
31.4 ± 2.2
39.7 ± 3.2
7.5 ± 1.1
19.5 ± 1.6
23.9 ± 1.8
20.9 ± 1.9
0.76 ± 0.03
0.53 ± 0.02
AR+ mice manifested right ventricular enlargement and impaired right ventricular systolic function, compared to AR- mice (Table 1). Impairment of right ventricular systolic function was more pronounced in mice with severe left ventricular systolic dysfunction (Figure 3).
The most important findings of this study are that aortic valve regurgitation occurs commonly in hypercholesterolemic Ldlr-/-/Apob100/100/Mttpfl/fl/Mx1Cre+/+ mice, leading to volume overload and pathological remodeling of both ventricles. Whereas hypercholesterolemia can be associated with a more complex "metabolic syndrome", Reversa mice only demonstrate about 10% increase in body mass and do not have elevated blood glucose compared to control mice, at the age reported here. These findings suggest that hypercholesterolemia alone is sufficient to cause aortic regurgitation.
It was previously reported that hypercholesterolemia causes disruption of aortic valve cusp architecture in humans  and in Reversa mice [6, 7]. This is the likely mechanism for aortic regurgitation since aortic root diameter did not differ significantly between groups of mice in the present study.
In humans, aortic valve regurgitation can also arise from diverse local and systemic processes involving the aorta and/or valve cusps. In retrospective series', conditions such as connective tissue disease, autoimmune or rheumatic disease, infection, trauma, and congenital malformation have all been associated with aortic regurgitation. These other factors may have masked the pathophysiologic importance of hypercholesterolemia, possibly explaining the failure to identify hypercholesterolemia as a risk factor for aortic regurgitation in the Framingham Study.
Comprehensive evaluation of a relatively small cohort of patients with familial hypercholesterolemia revealed a very high prevalence of aortic regurgitation: 26% and 80% in heterozygotes and homozygotes, respectively. Similar findings were reported in a younger cohort by Kolansky et al. However, since these studies involved patients undergoing cardiac catheterization, selection bias could have been quite significant. The current systematic study shows that hypercholesterolemia does indeed cause aortic regurgitation in mice.
The clinical course of patients with chronic aortic regurgitation is tightly linked to volume overload and the process of cardiac remodeling. Asymptomatic patients with aortic valve regurgitation develop systolic dysfunction at a rate of < 6% per year. Asymptomatic patients with LV dysfunction develop symptoms at a rate of > 25% per year, with an annual mortality > 10%. No medical interventions are known to ameliorate the severity of valve dysfunction, although the hemodynamic impact of aortic valve regurgitation may be mitigated with vasodilators[16, 17]. Aortic valve replacement surgery is recommended for patients with impending left ventricular dysfunction or heart failure.
Reversa mice offer an attractive model for future studies of the mechanisms by which compensatory cardiac growth in response to volume overload transforms to pathological cardiac remodeling. These mice spontaneously develop the sequelae of chronic left ventricular volume overload observed in humans with aortic regurgitation, and do so in a time frame that permits longitudinal investigation. Because the control group included hypercholesterolemic Reversa mice without aortic regurgitation, there was no doubt that the changes in ventricular structure and function were due to the valvular heart disease.
Right ventricular remodeling and systolic function are gaining acceptance as prognostic indicators in patients with heart disease. Patients with left ventricular systolic dysfunction have a worse prognosis when right ventricular systolic dysfunction is also present. Similarly, patients with mitral valve disease have a worse prognosis after valve surgery if they have concomitant right ventricular systolic dysfunction. Our findings indicate that right ventricular function is impaired in mice with significant aortic regurgitation, and that right ventricular systolic impairment is greater when the left ventricle begins to fail. The prognostic importance of these findings has not been ascertained in the setting of pure aortic regurgitation in mice or humans, and warrants further study.
The findings of this study have methodological implications. Image quality was constrained by the need to image mice with valvular heart disease during deep sedation following a single intraperitoneal injection. However, the data provide a level of "internal validation", by demonstrating that left- and right ventricular stroke volumes are nearly identical in the absence of detectable valve regurgitation, and by reporting relatively narrow parametric ranges in the absence of valvular disease. These attributes combine an experimental model with quantitative noninvasive methods conducive to longitudinal studies designed to investigate disease mechanisms and potential therapies for aortic regurgitation.
The mechanism by which aortic regurgitation spontaneously arises is usually imperfect coaptation of valve cusps during ventricular diastole. Reversa mice may not be unique in this respect. Tanaka et al  and Aikawa et al  reported anecdotal evidence of aortic regurgitation in Apoe-/- mice. Jordan et al reported anecdotal evidence of aortic valve regurgitation in mice with mucopolysaccharidosis. The current study is distinct from these earlier studies in that it assesses the causal role of hypercholesterolemia in aortic valve regurgitation in a systematic fashion, and provides quantitative determination of the severity of valve dysfunction and its impact on ventricular structure and function.
This study has several limitations. Reversa mice had very high cholesterol levels, which are seen clinically only in patients with homozygous mutations in the low-density lipoprotein receptor. The results are reported for a single time point – age 7.5 months. The long term risk of overt heart failure or death from aortic regurgitation in this mouse model has not yet been ascertained. A previous study reported that Reversa mice develop hemodynamically significant aortic valve stenosis by age 18 – 22 months. In that study, mice did not undergo CMR to assess the presence or severity of aortic regurgitation. It is not yet known whether individual mice undergo evolution of predominant valvular functional phenotype as they age. Also, we have not yet addressed whether the progression of aortic valve regurgitation can be retarded by reversal of the hypercholesterolemia. Future studies are warranted to address these questions.
Hypercholesterolemia causes aortic valve regurgitation with moderate prevalence in mice. When present, aortic valve regurgitation causes volume overload and pathological remodeling of both ventricles.
This work was funded by grant #'s RR017369 (RMW), P01HL062984(DDH), and K99HL092235(JDM) from the National Institutes of Health.
- Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL, Lehman B, Benjamin EJ: Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol. 1999, 83: 897-902. 10.1016/S0002-9149(98)01064-9.View ArticlePubMedGoogle Scholar
- Borer JS, Bonow RO: Contemporary approach to aortic and mitral regurgitation. Circulation. 2003, 108: 2432-2438. 10.1161/01.CIR.0000096400.00562.A3.View ArticlePubMedGoogle Scholar
- Borer JS: Aortic Valve Replacement for the asymptomatic patient with aortic regurgitation: a new piece of the strategic puzzle. Circulation. 2002, 106: 2637-2639. 10.1161/01.CIR.0000040585.99021.8E.View ArticlePubMedGoogle Scholar
- Roberts WC, Ko JM, Moore TR, Jones WH: Causes of pure aortic regurgitation in patients having isolated aortic valve replacement at a single US tertiary hospital (1993 to 2005). Circulation. 2006, 114: 422-429. 10.1161/CIRCULATIONAHA.106.622761.View ArticlePubMedGoogle Scholar
- Lieu HD, Withycombe SK, Walker Q, Rong JX, Walzem RL, Wong JS, Hamilton RL, Fisher EA, Young SG: Eliminating atherogenesis in mice by switching off hepatic lipoprotein secretion. Circulation. 2003, 107: 1315-1321. 10.1161/01.CIR.0000054781.50889.0C.View ArticlePubMedGoogle Scholar
- Weiss RM, Ohashi M, Miller JD, Young SG, Heistad DD: Calcific aortic valve stenosis in old hypercholesterolemic mice. Circulation. 2006, 114: 2065-2069. 10.1161/CIRCULATIONAHA.106.634139.View ArticlePubMedGoogle Scholar
- Miller JD, Weiss RM, Serrano KM, Brooks RM, Berry CJ, Zimmerman K, Young SG, Heistad DD: Normalization of hypercholesterolemia halts progression of aortic valve disease in mice. Circulation. 2009, 119: 2693-701. 10.1161/CIRCULATIONAHA.108.834614.PubMed CentralView ArticlePubMedGoogle Scholar
- Akat K, Borggrefe M, Kaden JJ: Aortic valve calcification: basic science to clinical practice. Heart. 2009, 95: 616-623. 10.1136/hrt.2007.134783.View ArticlePubMedGoogle Scholar
- Berry CJ, Thedens DR, Light-McGroary KA, Miller JD, Kutschke W, Zimmerman KA, Weiss RM: Effects of deep sedation or general anesthesia on cardiac function in mice undergoing cardiac magnetic resonance imaging. J Cardiovasc Magnet Res. 2009, 19: 16-10.1186/1532-429X-11-16.View ArticleGoogle Scholar
- Higgins CB, Wagner S, Kondo C, Suzuki J, Caputo GR: Evaluation of valvular heart disease with cine gradient echo magnetic resonance imaging. Circulation. 1991, 84 (Suppl I): 198-207.Google Scholar
- Glantz SA: Primer of Biostatistics Version 4.02 for Windows. 1996, New York: McGraw HillGoogle Scholar
- Freeman RV, Otto CM: Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation. 2005, 111: 3316-3326. 10.1161/CIRCULATIONAHA.104.486738.View ArticlePubMedGoogle Scholar
- Kawaguchi A, Miyatake K, Yutani C, Beppu S, Tsushima M, Yamamura T, Yamamoto A: Characteristic cardiovascular manifestation in homozygous and heterozygous familial hypercholesterolemia. Amer H J. 1999, 137: 410-418. 10.1016/S0002-8703(99)70485-0.View ArticleGoogle Scholar
- Kolansky DM, Cuchel M, Clark BJ, Paridon S, McCrindle BW, Siegers SE, Araujo L, Vohra Y, Defesche JC, Wilson JM, Rader DJ: Longitudinal Evaluation and Assessment of Cardiovascular Disease in Patients With Homozygous Familial Hypercholesterolemia. Am J Cardiol. 2008, 102: 1438-1443. 10.1016/j.amjcard.2008.07.035.View ArticlePubMedGoogle Scholar
- Bonow RO, Carabello BA, Chatterjee K, de Leon AC, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'Gara PT, O'Rourke RA, Otto CM, Shah PM, Shanewise JS: ACC/AHA 2006 Guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2006, 114: e84-231e. 10.1161/CIRCULATIONAHA.106.176857.View ArticlePubMedGoogle Scholar
- Scognamiglio R, Rahimtoola SH, Fasoli G, Nistri S, Dalla Volta S: Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function. N Engl J Med. 1994, 331: 1417-1423. 10.1056/NEJM199409153311101.View ArticleGoogle Scholar
- Evangelista A, Tornos P, Sambola A, Permanyer-Miralda G, Soler-Soler J: Long-term vasodilator therapy in patients with severe aortic regurgitation. N Engl J Med. 2005, 353: 1342-1349. 10.1056/NEJMoa050666.View ArticlePubMedGoogle Scholar
- Voelkel NF, Quaife RA, Leinwand LA, Barst RJ, McGoon MD, Meldrum DR, Dupuis J, Long CS, Rubin LJ, Smart FW, Suzuki YJ, Gladwin M, Denholm EM, Gail DB: Right Ventricular Function and Failure: Report of a National Heart, Lung, and Blood Institute Working Group on Cellular and Molecular Mechanisms of Right Heart Failure. Circulation. 2006, 114: 1883-1891. 10.1161/CIRCULATIONAHA.106.632208.View ArticlePubMedGoogle Scholar
- Ghio S, Gavazzi A, Campana C, Inserra C, Klersy C, Sebastiani R, Arbustini E, Recusani F, Tavazzi L: Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol. 2001, 37: 183-188. 10.1016/S0735-1097(00)01102-5.View ArticlePubMedGoogle Scholar
- Haddad F, Denault AY, Couture , Cartier R, Pellerin M, Levesque S, Lambert J, Tardif JC: Right ventricular myocardial performance index predicts perioperative mortality and circulatory failure in high-risk valvular surgery. J Am Soc Echocardiogr. 2007, 20: 1065-1072. 10.1016/j.echo.2007.02.017.View ArticlePubMedGoogle Scholar
- Tanaka K, Sata M, Fukuda D, Suematsu Y, Motomura N, Takamoto S, Hirata Y, Nagai R: Age-associated aortic stenosis in apolipoprotein E-deficient mice. J Am Coll Cardiol. 2005, 46: 134-141. 10.1016/j.jacc.2005.03.058.View ArticlePubMedGoogle Scholar
- Aikawa E, Nahrendorf M, Sosnovik D, Lok VM, Jaffer FA, Aikawa M, Weissleder R: Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. Circulation. 2007, 115: 377-386. 10.1161/CIRCULATIONAHA.106.654913.View ArticlePubMedGoogle Scholar
- Jordan MC, Zheng Y, Ryazantsev S, Rozengurt N, Roos KP, Neufeld EF: Cardiac manifestations in the mouse model of mucopolysaccharidosis I. Mol Genet Metab. 2005, 86: 233-43. 10.1016/j.ymgme.2005.05.003.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.